Polar Capital Holdings’s Madrigal Pharmaceuticals MDGL Stock Holding History

Polar Capital Holdings’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$131M	Sell	244,274 -45,036	-16%	-$23.1M	0.31%	69
2026 Q1	$151M	Buy	289,310 +19,159	+7%	+$9.15M	0.54%	46
2025 Q4	$157M	Buy	270,151 +4,997	+2%	+$2.55M	0.61%	46
2025 Q3	$122M	Buy	265,154 +39,744	+18%	+$14.8M	0.59%	52
2025 Q2	$68.2M	Buy	225,410 +75,190	+50%	+$22.4M	0.36%	73
2025 Q1	$49.8M	Buy	150,220 +12,500	+9%	+$4.11M	0.3%	95
2024 Q4	$42.5M	Buy	137,720 +37,245	+37%	+$10.5M	0.24%	105
2024 Q3	$21.3M	Sell	100,475 -24,825	-20%	-$6.35M	0.1%	141
2024 Q2	$35.1M	Buy	125,300 +95	+0.1%	+$22.6K	0.21%	104
2024 Q1	$33.4M	Buy	+125,205	New	+$29.5M	0.18%	109

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Polar Capital Holdings's MDGL Position: Q2 2026 in Review

Polar Capital Holdings reduced its Madrigal Pharmaceuticals (MDGL) stake by 16% in Q2 2026, selling an estimated $23.1M and leaving 244,274 shares worth $131M. The position accounts for 0.31% of the portfolio, ranked #69.

Polar Capital Holdings first reported a position in MDGL in Q1 2024 and has held it in 10 quarters since. The position peaked at $157M in Q4 2025. 413 funds tracked by Wall St. Rank hold MDGL as of Q2 2026.

Polar Capital Holdings held 244,274 shares of Madrigal Pharmaceuticals worth $131M as of Q2 2026.
Polar Capital Holdings sold 45,036 Madrigal Pharmaceuticals shares in Q2 2026, an estimated $23.1M.
Madrigal Pharmaceuticals made up 0.31% of Polar Capital Holdings's portfolio in Q2 2026, its #69 holding.
Polar Capital Holdings first reported a position in Madrigal Pharmaceuticals in Q1 2024 and has held it in 10 quarters since.
Polar Capital Holdings's Madrigal Pharmaceuticals position peaked at $157M in Q4 2025.
413 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q2 2026.

Based on Polar Capital Holdings's 13F filing for Q2 2026, filed 14 Aug 2026.